A miRNA expression signature that separates between normal and malignant prostate tissues

Carlsson, Jessica; Davidsson, Sabina; Helenius, Gisela; Karlsson, Mats G.; Lubovac, Zelmina; Andrén, Ove; Olsson, Björn; Klinga-Levan, Karin

doi:10.1186/1475-2867-11-14

Cited by 44 publications

(39 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Both miR-26a and miR-26b have been identified as regulators of EZH2:54,58 for miR-26a, this was also described in PCa 58,59. In various PCa cell lines, the overexpression of miR-26a and miR-26b represses both EZH2 mRNA and protein causing a reduction in cellular proliferation 55,58,60. Some researchers showed that the expression of miR-26a progressively decreased with increasing GS 61.…”

Section: Discussionmentioning

confidence: 95%

See 1 more Smart Citation

Different levels of serum microRNAs in prostate cancer and benign prostatic hyperplasia: evaluation of potential diagnostic and prognostic role

Cochetti¹,

Poli²,

Guelfi³

et al. 2016

OTT

View full text Add to dashboard Cite

IntroductionDiagnosis of prostate cancer (PCa) is based on prostate biopsy that is performed when prostate specific antigen (PSA) is persistently altered over time and/or abnormal digital rectal examination is found. Serum PSA levels increase in both PCa and benign prostatic hyperplasia, leading to an increased number of unnecessary biopsies. There is an urgent need to unravel PCa-specific molecular signatures.Patients and methodsThis study aimed at characterizing a panel of circulating micro RNAs (miRNAs) that could distinguish PCa from benign prostatic hyperplasia in a population of age-matched patients with increased PSA levels. Both miRNAs targeting genes involved in PCa onset and miRNAs whose role in PCa has been highlighted in other studies were included. For this purpose, let-7c, let-7e, let-7i, miR-26a-5p, miR-26b-5p, miR-24-3p, miR-23b-3p, miR-27-b-3p, miR-106a-5p, miR-20b-5p, miR-18b-5p, miR-19b-2-5p, miR-363-3p, miR-497, miR-195, miR-25-3p, miR-30c-5p, miR-622, miR-874-3p, miR-346 and miR-940 were assayed through real-time PCR in 64 patients with PCa and compared with 60 patients with benign prostatic hyperplasia. The ability of miRNAs to predict the stage of disease was also analyzed.ResultsLet-7c, let-7e, let-7i, miR-26a-5p, miR-26b-5p, miR-18b-5p and miR-25-3p were able to discriminate patients with PCa from those harboring benign prostatic hyperplasia, both presenting altered PSA levels (>3 ng/mL). MiR-25-3p and miR-18b-5p showed the highest sensitivity and specificity to predict PCa, respectively. The combination of these two miRNAs improved the overall sensitivity. A correlation between pathological Gleason score and miRNA expression levels was reported; miR-363-3p, miR-26a-5p, miR-26b-5p, miR-106a-5p, miR-18b-5p, miR-25-3p and let-7i decreased in expression concomitantly with an increase in malignancy.ConclusionThis study confirms serum miRNAs to be reliable candidates for the development of minimally invasive biomarkers for the diagnosis and prognosis of PCa, particularly in those cases where PSA acts as a flawed marker.

show abstract

Section: Discussionmentioning

confidence: 95%

“…In PCa, both miR-26a and miR-26b target La-related protein 1 53. At the tissue level, miR-26a30,54,55 and miR-26b30 are significantly downregulated in malignant tissue samples from prostatectomy specimens compared to matched nonmalignant counterparts 56. Nonetheless, increased levels in PCa tissues were also reported 37,39,57.…”

Section: Discussionmentioning

confidence: 96%

Different levels of serum microRNAs in prostate cancer and benign prostatic hyperplasia: evaluation of potential diagnostic and prognostic role

Cochetti¹,

Poli²,

Guelfi³

et al. 2016

OTT

View full text Add to dashboard Cite

show abstract

“…Numerous miRNAs have been suggested to play vital roles in gastric cancer development and progression, functioning in a either a cooperative manner or alone (10)(11)(12). An independent study by Kogo et al reported that miR-146a levels were dramatically decreased in gastric cancer, and more importantly, lower levels of miR-146a were associated with lymph node metastasis and venous invasion (13).…”

Section: Discussionmentioning

confidence: 99%

Expression and clinical significance of the microRNA-200 family in gastric cancer

Chang

Huo

et al. 2015

Oncology Letters

View full text Add to dashboard Cite

Abstract. Gastric cancer is one of the most common malignant tumors and one of the leading causes of cancer-related mortality. Recent studies have revealed that there is a difference in microRNA (miR/miRNA) profiles between cancerous and normal tissues. To find a potentially useful prognostic predictor and a promising therapeutic tool for gastric cancer, the present study investigated the expression and clinical significance of the miR-200 family in gastric cancer. The miR-200 family has five members: hsa-miR-200a, hsa-miR-200b, hsa-miR-200c, hsa-miR-141 and hsa-miR-429. In 46 clinical samples of gastric cancer and paired non-cancerous tissues, the present study observed that the expression levels of the miR-200 family in the cancer tissues were significantly lower than those in the non-cancerous tissues (P<0.001). Lower levels of the five family members were associated with histological grade and the presence of an intravascular cancer embolus (P<0.05). The results revealed that the miR-200 family is downregulated in gastric cancer, and that there are significant differences in the expression of the miR-200 family between normal and cancer tissues. The miR-200 family may therefore become a potentially useful prognostic predictor of the aggressiveness of gastric cancer and a possible therapeutic tool in affected patients.

show abstract

“…In contrast, Porkka et al [84] comparing 319 miRNAs in nine PCa and four BPH tissues showed that eight miRNAs were upregulated and 22 were downregulated. More recently, Carlsson et al [85], evaluating 667 miRNA, found nine miRNAs that consistently differ between malignant prostate tissues and the adjacent normal tissue from each case. Srivastava et al [86] showed that miR-205, miR-214, miR-221 and miR-99b were significantly downregulated in PCa tissues compared to adjacent normal tissue.…”

Section: Mirna Expression In Pca Tissuementioning

confidence: 99%

miRNAs as novel biomarkers in the management of prostate cancer

Filella

Foj

2017

Clinical Chemistry and Laboratory Medicine (CCLM)

100

View full text Add to dashboard Cite

microRNAs (miRNAs) are small non-coding RNAs that control gene expression posttranscriptionally and are part of the giant non codifying genoma. Cumulating data suggest that miRNAs are promising potential biomarkers for many diseases, including cancer. Prostate cancer (PCa) detection is currently based in the serum prostate-specific antigen biomarker and digital rectal examination. However, these methods are limited by a low predictive value and the adverse consequences associated with overdiagnosis and overtreatment. New biomarkers that could be used for PCa detection and prognosis are still needed. Recent studies have demonstrated that aberrant expressions of microRNAs are associated with the underlying mechanisms of PCa. This review attempts to extensively summarize the current knowledge of miRNA expression patterns, as well as their targets and involvement in PCa pathogenesis. We focused our review in the value of circulating and urine miRNAs as biomarkers in PCa patients, highlighting the existing discrepancies between different studies, probably associated with the important methodological issues related to their quantitation and normalization. The majority of studies have been performed in serum or plasma, but urine obtained after prostate massage appears as a new way to explore the usefulness of miRNAs. Large screening studies to select a miRNA profile have been completed, but bioinformatics tools appear as a new approach to select miRNAs that are relevant in PCa development.Promising preliminary results were published concerning miR-141, miR-375 and miR-21, but larger and prospective studies using standardized methodology are necessary to define the value of miRNAs in the detection and prognosis of PCa.

show abstract

A miRNA expression signature that separates between normal and malignant prostate tissues

Cited by 44 publications

References 45 publications

Different levels of serum microRNAs in prostate cancer and benign prostatic hyperplasia: evaluation of potential diagnostic and prognostic role

Different levels of serum microRNAs in prostate cancer and benign prostatic hyperplasia: evaluation of potential diagnostic and prognostic role

Expression and clinical significance of the microRNA-200 family in gastric cancer

miRNAs as novel biomarkers in the management of prostate cancer

Contact Info

Product

Resources

About